Hudson Bay Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $719K | Sell |
5,690
-94,320
| -94% | -$12.4M | ﹤0.01% | 971 |
|
|
2026
Q1 | $13.9M | Sell |
100,010
-36,861
| -27% | -$5.16M | 0.05% | 247 |
|
|
2025
Q4 | $16.8M | Buy |
136,871
+124,857
| +1,039% | +$15.2M | 0.06% | 247 |
|
|
2025
Q3 | $1.33M | Sell |
12,014
-12,411
| -51% | -$1.41M | ﹤0.01% | 813 |
|
|
2025
Q2 | $2.71M | Sell |
24,425
-106,901
| -81% | -$11.4M | 0.01% | 712 |
|
|
2025
Q1 | $14.7M | Buy |
+131,326
| New | +$13.6M | 0.05% | 317 |
|
|
2024
Q4 | – | Sell |
-80,853
| Closed | -$7.28M | – | 987 |
|
|
2024
Q3 | $6.78M | Sell |
80,853
-64,147
| -44% | -$4.89M | 0.03% | 359 |
|
|
2024
Q2 | $9.95M | Sell |
145,000
-329,108
| -69% | -$22M | 0.05% | 234 |
|
|
2024
Q1 | $34.7M | Buy |
474,108
+426,608
| +898% | +$32.8M | 0.19% | 73 |
|
|
2023
Q4 | $3.85M | Sell |
47,500
-200,000
| -81% | -$15.6M | 0.02% | 340 |
|
|
2023
Q3 | $18.5M | Buy |
247,500
+193,100
| +355% | +$14.9M | 0.15% | 97 |
|
|
2023
Q2 | $4.19M | Buy |
+54,400
| New | +$4.34M | 0.03% | 346 |
|
|
2022
Q3 | – | Sell |
-25,000
| Closed | -$1.54M | – | 1275 |
|
|
2022
Q2 | $1.54M | Buy |
+25,000
| New | +$1.55M | 0.01% | 846 |
|
|
2021
Q1 | – | Sell |
-35,000
| Closed | -$2.04M | – | 889 |
|
|
2020
Q4 | $2.04M | Sell |
35,000
-50,000
| -59% | -$3.02M | 0.02% | 375 |
|
|
2020
Q3 | $5.37M | Buy |
+85,000
| New | +$5.89M | 0.08% | 211 |
|
|
2020
Q1 | – | Sell |
-95,000
| Closed | -$6.17M | – | 536 |
|
|
2019
Q4 | $6.17M | Buy |
95,000
+85,000
| +850% | +$5.54M | 0.14% | 141 |
|
|
2019
Q3 | $634K | Sell |
10,000
-10,000
| -50% | -$654K | 0.02% | 336 |
|
|
2019
Q2 | $1.35M | Sell |
20,000
-15,000
| -43% | -$987K | 0.03% | 308 |
|
|
2019
Q1 | $2.27M | Buy |
+35,000
| New | +$2.33M | 0.03% | 443 |
|
|
2018
Q2 | – | Sell |
-2,700
| Closed | -$191K | – | 866 |
|
|
2018
Q1 | $204K | Buy |
+2,700
| New | +$215K | ﹤0.01% | 727 |
|
|
2017
Q3 | – | Sell |
-70,000
| Closed | -$4.96M | – | 440 |
|
|
2017
Q2 | $4.96M | Buy |
70,000
+40,000
| +133% | +$2.66M | 0.1% | 195 |
|
|
2017
Q1 | $2.04M | Buy |
30,000
+23,800
| +384% | +$1.67M | 0.03% | 473 |
|
|
2016
Q4 | $444K | Buy |
+6,200
| New | +$461K | 0.01% | 545 |
|
|
2016
Q3 | – | Sell |
-21,450
| Closed | -$1.79M | – | 465 |
|
|
2016
Q2 | $1.79M | Buy |
+21,450
| New | +$1.9M | 0.06% | 197 |
|
|
2014
Q3 | – | Sell |
-105,400
| Closed | -$8.74M | – | 221 |
|
|
2014
Q2 | $8.74M | Buy |
+105,400
| New | +$8.2M | 0.27% | 78 |
|
Other funds holding GILD
Hudson Bay Capital Management's GILD Position: Q2 2026 in Review
Hudson Bay Capital Management reduced its Gilead Sciences (GILD) stake by 94% in Q2 2026, selling an estimated $12.4M and leaving 5,690 shares worth $719K. The position accounts for ﹤0.01% of the portfolio, ranked #971.
Hudson Bay Capital Management first reported a position in GILD in Q2 2014 and has held it in 25 quarters since. The position peaked at $34.7M in Q1 2024. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Hudson Bay Capital Management held 5,690 shares of Gilead Sciences worth $719K as of Q2 2026.
- Hudson Bay Capital Management sold 94,320 Gilead Sciences shares in Q2 2026, an estimated $12.4M.
- Gilead Sciences made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #971 holding.
- Hudson Bay Capital Management first reported a position in Gilead Sciences in Q2 2014 and has held it in 25 quarters since.
- Hudson Bay Capital Management's Gilead Sciences position peaked at $34.7M in Q1 2024.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.